Fundraising Fox
PDS Biotechnology Corp.
NASDAQ: PDSBNorth Brunswick, US · 3 known investors
Find your way into PDS Biotechnology Corp.
Sign up to see every warm intro you have to PDS Biotechnology Corp.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PDS Biotechnology Corp. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PDS Biotech develops T cell activating immunotherapies for cancer and infectious disease vaccines in clinical stages. The company operates proprietary platforms and maintains partnerships with major healthcare institutions including Merck, MD Anderson Cancer Center, National Cancer Institute, and Mayo Clinic.
Founders & leadership
FK
Frank K. Bedu-AddoFounderFrank Bedu-Addo is a biotech executive with experience in drug development, pharmaceutical operations, and raising both private and public financing. He has held leadership roles at drug development companies, served on boards of private and public companies, and has published research on protein drug development and nano-therapeutics.
FB
Frank Bedu-AddoPresident, Chief Executive Officer, Principal Executive Officer and DirectorFrank Bedu-Addo is a biotech executive with background in drug development, fundraising, and regulatory affairs. He has led private and public biotech companies through clinical development stages and negotiated partnerships with pharmaceutical and academic institutions.
GL
Gregory L. ConnChief Scientific Officer
LB
Lars BoesgaardChief Financial OfficerAn international finance executive with divisional and corporate management experience, Lars Boesgaard has led private and public funding activities, including IPO work, and has expertise in financial reporting, cost accounting, internal controls, and SOX compliance across multiple regions.
ST
Stephan ToutainChief Operating OfficerStephan Toutain is Chief Operating Officer at PDS Biotechnology Corp., which develops T cell activating immunotherapies for cancer and infectious disease vaccines. He brings experience as a biotech/pharmaceutical executive with prior involvement in commercial operations across neurology, hematology, nephrology, oncology, and cardiovascular therapeutic areas, including work on orphan drug and rare disease development.
Investors · 3
Elevate Ventureslisted by Elevate VenturesIndianapolis · $20K – $2M
How we know: the VCSheet dataset · Not right? Tell us
EMV Capitallisted by EMV CapitalLondon
How we know: EMV Capital's portfolio page · the S-1 prospectus · Not right? Tell us
Yorkville AdvisorsreportedMountainside
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$2M disclosed across 2 of 3 rounds · 2016–2025
- Undisclosed amountregistered direct offeringNov 2025Source ↗
▶$1.1MraisedSep 2016 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedSep 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank K. Bedu-AddoExecutive Officer
- Offering amount
- $10M
- Amount sold
- $1.1M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$902.5KraisedAug 2016 · 12 investors · BiotechnologyRule 506(b)
▶$902.5KraisedAug 2016 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank K. Bedu-AddoExecutive Officer
- Offering amount
- $1M
- Amount sold
- $902.5K
- Minimum investment
- $10K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies working in the same space as PDS Biotechnology Corp..
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $174.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $166.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $149.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Acquisitions · 1
Early investors' stakes continue via these dealsEdge Therapeutics
Hospital-based therapies for acute, life-threatening neurological conditions. (NASDAQ: EDGE)
Frequently asked questions
- What does PDS Biotechnology Corp. do?
- PDS Biotech develops T cell activating immunotherapies for cancer and infectious disease vaccines in clinical stages. The company operates proprietary platforms and maintains partnerships with major healthcare institutions including Merck, MD Anderson Cancer Center, National Cancer Institute, and Mayo Clinic.
- Who founded PDS Biotechnology Corp.?
- PDS Biotechnology Corp. was founded by Frank K. Bedu-Addo.
- Who are PDS Biotechnology Corp.'s investors?
- PDS Biotechnology Corp.'s investors include Elevate Ventures, EMV Capital, Yorkville Advisors.
- How much funding has PDS Biotechnology Corp. raised?
- PDS Biotechnology Corp. has disclosed $2M raised across 2 of its 3 known rounds.
- Where is PDS Biotechnology Corp. headquartered?
- PDS Biotechnology Corp. is headquartered in North Brunswick, US.